“It is our mission to develop the next generation of (nano)medicines; low in side-effects and high in efficacy. Our nanoparticle platform promises exactly this; it uses organ- or cell-targeting to prevent side-effects and it uses mRNA, the software of the body, to treat diseases with unprecedented efficacy”, tells Sander van Asbeck, CEO of Mercurna. “Besides the progress on the CKD-drug, we’ve also become very experienced in the production of mRNA with a constant quality. This allowed us to launch our custom mRNA synthesis service with which we provide academics and businesses with mRNA. In case you’re interested in learning more about this, about the Pivot Park Friends & Family discount we currently offer on custom mRNA or about our company, please let me know!”